Dr Graham Bell has been working in Biotechnology companies for over 20 years. He is currently the Chief Executive Officer at Carbon Life Group Ltd who will be making the initial investment in the spinout. He also runs his own consultancy company Two Bells Consulting Ltd, which provides interim management, strategic and operational advice to biotechnology companies. He is retained as a monitoring officer by InnovateUK where he currently monitors 18 Biomedical catalyst grants ranging from therapeutics, clinical devices and diagnostic programmes. He was previously in charge of corporate development at Cyclacel ltd, overseeing the development of a Cambridge UK based genomics division and running the merger process which took Cyclacel onto the NASDAQ through a reverse merger. He was a founder and director of NeuroBio Ltd which carries out research and development of therapeutic agents for Alzheimers disease.
Dr Mike Finnen has wide-ranging senior management experience in the pharmaceutical industry at both large international pharma and start-up companies, working in both discovery and developmental areas. He has extensive project management experience in both laboratory and clinical project development and has a successful track record in company formation based around new IP. Prior to founding RelaxSol Mike was Head of Operations for the Edinburgh BioQuarter Commercialisation programme at the College of Medicine and Veterinary Medicine at the University of Edinburgh.
Richard Weller has significant experience and expertise across the Dermatological spectrum. He has consulted for commercial companies on Dermatological product development including Mentholatum, Estee Lauder, L’Oreal, Insense and ProStrakan. The applications on which he has collaborated extend from cosmetic to pharmaceutical. He has led or participated in clinical research supporting this consultancy work in all phases of development from in vitro development/animal testing through to Phase 3 clinical trials. He has co-founded one company and registered a patent.
Yiyuan earned his first degree in Biology from Sichuan University, China and subsequently obtained an MSc in Bioprocess Engineering from the University of Sheffield. He has recently completed a PhD in structural biology (drug discovery) at the University of Edinburgh. In 2012 Yiyuan founded the Carbon Life Science Group. Carbon Life specialises in investment and technology transfer between UK and China in the life science sector. Carbon Life invested RelaxSol in 2015 as key investor.
Professor Martin Feelisch, After the study of pharmacy Martin earned his PhD in pharmacology from the Heinrich-Heine University in Dusseldorf in 1988. He was appointed to the Personal Chair of Experimental Medicine & Integrative Biology at Southampton University in April 2012, following a number of other senior research positions in both academia and industry in the USA and Europe.